Showing 4301-4310 of 8850 results for "".
- Large Registries Leave Data Gaps for Melanoma in Black Patientshttps://practicaldermatology.com/news/large-registries-leave-gaps-in-data-on-melanoma-in-black-patients/2462232/New research published in JAMA Dermatology provides crucial patient-level and tumor-level insights into melanoma in Black patients that has been lacking in large registiries.
- Highlights from Maui Derm 2024https://practicaldermatology.com/news/highlights-from-maui-derm-2024/2462227/The Maui Derm 2024 Conference showcased a wide array of advancements in dermatology, from innovative treatments to exciting new therapies, to business opportunities to the latest research. Here, Practical Dermatology recap
- Important FDA Approvals in 2023 Lead to New, Exciting Treatments in 2024https://practicaldermatology.com/news/important-fda-approvals-in-2023-lead-to-new-exciting-treatments-in-2024/2462219/A slew of big approvals for new therapies in 2023 has increased the armamentarium for dermatologists treating many conditions going into 2024, according to an opening presentation at Maui Derm 2024. <
- FDA Gives Nod to Marketing DermaSensor for Skin Lesion Evaluationhttps://practicaldermatology.com/news/fda-gives-nod-to-dermasensor-for-skin-lesion-evaluation/2462213/The U.S Food and Drug Administration (FDA) announced that it has granted authorization for marketing for the DermaSensor (DermaSensor Inc.) prescription device, indicated for the evaluation of skin lesions suggestive of melanoma, basal cell carcinoma, and/or squamous cell carcinoma in patients ag
- Insufficient Disease Control in Moderate-to-Severe AD: Year-long Longitudinal Study Reveals Treatment Gapshttps://practicaldermatology.com/news/insufficient-disease-control-in-severe-atopic-dermatitis-a-12-month-longitudinal-study-reveals-treatment-gaps/2462212/A recent study presented at the Revolutionizing Atopic Dermatitis (RAD) Virtual Conference highlighted has shed light on the persistent issue of therapeuti
- FDA Deems Vaporized Hydrogen Peroxide an Established Method of Sterilizationhttps://practicaldermatology.com/news/fda-deems-vaporized-hydrogen-peroxide-an-established-method-of-sterilization/2462205/The U.S. Food and Drug Administration (FDA) announced that it now considers vaporized hydrogen peroxide (VHP) as an established method of sterilization for medical devices. In what the agency called a recognition of its long-time effectiveness, it revised the final guidance on the
- Melanoma Rates Among Non-Hispanic American Indian/Alaska Natives Vary by Age, Region: Studyhttps://practicaldermatology.com/news/melanoma-rates-among-non-hispanic-american-indianalaska-native-individuals/2462199/A new study in JAMA Dermatology shed light on trends and incidence rates of invasive cutaneous melanoma in non-Hispanic American Indian/Alaska Native individuals. The cross-sectional observational study, focusing on a period from 1999 to 2019, included data drawn from a populati
- Seaweed- and Carbonated Water-based Hydrogel Shows Promise for Treatment of Skin Woundshttps://practicaldermatology.com/news/revolutionary-seaweed-and-carbonated-water-based-hydrogel-for-treating-skin-wounds/2462184/Results from a new study suggested promise for a new seaweed- and carbonated water-based hydrogel that aims to prevent the temporary dilation of wound sites. Researchers developed a low-adhe
- FDA Approves Adbry (tralokinumab-ldrm) for Treatment of Moderate-to-Severe AD in Pediatric Patients Aged 12-17 Yearshttps://practicaldermatology.com/news/fda-approval-of-tralokinumab-ldrm-for-the-treatment-of-moderate-to-severe-atopic-dermatitis-in-pediatric-patients-aged-12-17-years/2462185/The US Food and Drug Administration (FDA) has expanded the approval of Adbry® (tralokinumab-ldrm) to include pediatric patients aged 12 to 17 years with moderate-to-severe atopic dermatitis (AD) whose disease is not adequately controlled with topical prescription therapies
- Scinai Announces Promising Results in a Psoriatic Human Skin Modelhttps://practicaldermatology.com/news/scinai-announces-promising-results-in-a-psoriatic-human-skin-model/2462180/Scinai Immunotherapeutics Ltd. announced a successful preclinical trial result for its anti-IL-17 VHH antibody (NanoAb) as a local treatment for moderate plaque psoriasis. The study, designed to evaluate the anti-inflammatory effects of NanoAbs, used proprietary induced human